/
/
/

Onesource Specialty Pharma Results

Financial overview

CAGR%
Sales
Profits
Returns
ROE
10Y5Y3YTTM
--232%-2%
----327%
----17%
-24%-24%-21%-1%

Peer Comparison

Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
ZYDUSLIFE
CIPLA
LAURUSLABS
LUPIN
MANKIND
DRREDDY
AUROPHARMA
ONESOURCE
PriceM.Cap (₹)PE RatioEPS (₹)EV/EBITDAAnnual PAT
1,916₹463791 Cr38.3412.0762.82₹11479 Cr
9,250₹245081 Cr83.7934.04128.41₹2568 Cr
4,905.5₹190351 Cr87.2816.7297.06₹2163 Cr
1,143₹114833 Cr25.449.4262.53₹5040 Cr
1,394.7₹114163 Cr33.879.7757.87₹3879 Cr
1,868.5₹100660 Cr92.066.829.25₹889 Cr
2,132₹98431 Cr17.830.95154.36₹5333 Cr
2,368.8₹98305 Cr48.1313.7571.08₹1913 Cr
1,155₹96906 Cr30.075.3263.99₹4196 Cr
1,637.3₹95300 Cr25.6717.9596.84₹3505 Cr
1,575.7₹17715 Cr2.1820.44-₹74 Cr

Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
₹449 Cr₹428 Cr₹290 Cr₹376 Cr₹327 Cr₹426 Cr₹393 Cr₹334 Cr₹292 Cr₹73 Cr₹56 Cr₹34 Cr
₹4 Cr₹2 Cr₹5 Cr₹3 Cr₹5 Cr₹3 Cr₹7 Cr₹4 Cr₹4 Cr₹3 Cr₹1 Cr₹9 L
₹453 Cr₹430 Cr₹295 Cr₹379 Cr₹333 Cr₹429 Cr₹399 Cr₹338 Cr₹296 Cr₹76 Cr₹57 Cr₹34 Cr
₹397 Cr₹408 Cr₹343 Cr₹339 Cr₹307 Cr₹312 Cr₹319 Cr₹325 Cr₹296 Cr₹95 Cr₹86 Cr₹91 Cr
₹127 Cr₹94 Cr₹22 Cr₹110 Cr₹94 Cr₹185 Cr₹149 Cr₹82 Cr₹68 Cr-₹16 L-₹9 Cr-₹38 Cr
₹31 Cr₹23 Cr₹38 Cr₹34 Cr₹27 Cr₹33 Cr₹46 Cr₹45 Cr₹42 Cr₹20 Cr₹26 Cr₹25 Cr
₹20 Cr-₹29 L-₹93 Cr₹6 Cr-₹4 Cr₹84 Cr-₹67 Cr-₹37 Cr-₹47 Cr-₹40 Cr-₹161 Cr-₹87 Cr
₹25 Cr₹5 Cr-₹89 Cr₹10 Cr-₹19 L₹99 Cr-₹69 Cr-₹42 Cr-₹6 Cr-₹40 Cr-₹130 Cr-₹114 Cr

Balance Sheet

Consolidated
Standalone
%
Name
Equity And Liabilities
Share Capital
Share Warrants & Outstandings
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Secured Loans
Unsecured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022
₹11 Cr₹11 Cr₹4 Cr₹4 Cr₹3 Cr
₹7 Cr₹12 Cr₹8 Cr₹6 Cr₹0
₹5813 Cr₹5857 Cr₹384 Cr₹775 Cr₹1009 Cr
₹5813 Cr₹5857 Cr₹384 Cr₹775 Cr₹1009 Cr
₹5831 Cr₹5881 Cr₹396 Cr₹785 Cr₹1012 Cr
₹564 Cr₹181 Cr₹12 Cr₹285 Cr₹597 Cr
₹0₹38 Cr₹259 Cr₹50 Cr₹0
₹135 Cr₹155 Cr₹0₹0₹0
₹220 Cr₹166 Cr₹8 Cr₹21 Cr₹22 Cr
₹18 Cr₹16 Cr₹2 Cr₹2 Cr₹2 Cr
₹937 Cr₹556 Cr₹282 Cr₹358 Cr₹621 Cr
₹375 Cr₹176 Cr₹81 Cr₹95 Cr₹63 Cr
₹476 Cr₹478 Cr₹536 Cr₹573 Cr₹559 Cr
₹576 Cr₹436 Cr₹10 Cr₹194 Cr₹184 Cr
₹27 Cr₹24 Cr₹4 Cr₹4 Cr₹3 Cr
₹1454 Cr₹1114 Cr₹631 Cr₹865 Cr₹809 Cr
₹8222 Cr₹7550 Cr₹1309 Cr₹2009 Cr₹2442 Cr
₹1287 Cr₹1165 Cr₹1137 Cr₹1144 Cr₹150 Cr
₹1276 Cr₹772 Cr₹562 Cr₹837 Cr₹1154 Cr
₹6844 Cr₹6666 Cr₹1139 Cr₹1633 Cr₹1392 Cr
₹826 Cr₹549 Cr₹277 Cr₹271 Cr₹160 Cr
₹6017 Cr₹6118 Cr₹863 Cr₹1361 Cr₹1231 Cr
₹314 Cr₹60 Cr₹43 Cr₹191 Cr₹68 Cr
₹10 Cr₹7 Cr₹4 Cr₹0₹0
₹10 Cr₹7 Cr₹4 Cr₹0₹0
₹227 Cr₹121 Cr₹77 Cr₹82 Cr₹210 Cr
₹17 L₹41 L₹80 L₹2 Cr₹0
₹6784 Cr₹6464 Cr₹1132 Cr₹1780 Cr₹1931 Cr
₹5 Cr₹9 Cr₹16 Cr₹5 Cr₹0
₹439 Cr₹158 Cr₹11 Cr₹133 Cr₹275 Cr
₹690 Cr₹417 Cr₹55 Cr₹4 Cr₹24 Cr
₹98 Cr₹301 Cr₹60 Cr₹80 Cr₹170 Cr
₹29 Cr₹40 Cr₹8 Cr₹1 Cr₹31 Cr
₹177 Cr₹162 Cr₹26 Cr₹6 Cr₹11 Cr
₹1438 Cr₹1086 Cr₹176 Cr₹228 Cr₹511 Cr
-₹16 Cr-₹27 Cr-₹454 Cr-₹637 Cr-₹298 Cr
₹8222 Cr₹7550 Cr₹1309 Cr₹2009 Cr₹2442 Cr
₹508₹513₹97₹194₹333
₹508₹513₹97₹194₹333

Cash Flow

Consolidated
Standalone
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Cash & Cash Equivalent on Amalgamation / Take over / Merger
Closing Cash & Cash Equivalent
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022
-₹92 Cr-₹68 Cr-₹391 Cr-₹800 Cr-₹231 Cr
₹386 Cr₹427 Cr₹288 Cr₹604 Cr₹147 Cr
-₹277 Cr-₹420 Cr-₹4 Cr₹22 Cr-₹332 Cr
₹17 Cr-₹61 Cr-₹107 Cr-₹174 Cr-₹416 Cr
₹9 Cr-₹68 Cr-₹107 Cr-₹163 Cr-₹416 Cr
-₹495 Cr-₹201 Cr₹511 Cr-₹68 Cr-₹692 Cr
₹359 Cr₹412 Cr-₹391 Cr₹118 Cr₹1162 Cr
-₹127 Cr₹143 Cr₹13 Cr-₹112 Cr₹54 Cr
₹165 Cr₹22 Cr₹9 Cr₹122 Cr₹67 Cr
₹0₹2 L₹0₹0₹0
₹38 Cr₹165 Cr₹22 Cr₹9 Cr₹122 Cr

Fundamental Ratios

Consolidated
Standalone
Empty box

No results found

Share Price Live Stats

Open (₹)1,559.00
Volume (₹)1.19 L
High (₹)1,596.60
Upper Circuit1,853.20
Low (₹)1,546.00
Lower Circuit1,235.60
Prev Close1,544.40
52W High (₹)1,925.00
Price1,575.70
52W Low (₹)1,057.00

Share Market Cap & Key Ratios Overview

M.Cap (₹)17715.20 Cr
Div. Yield (%)0.00
PE Ratio0.00
Debt to Equity0.22
Price to Book2.90
Book Value508.17
EPS (TTM)-4.24
Face Value1.00
ROE (%)-1.26

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
LUPINNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
ONESOURCENSE
LTP
1W Low
1W High
Market cap (₹)
1916-4 (-0.21%)
1905
1984.80
4,63,791Cr
9250+11 (0.12%)
9087
9467
2,45,081Cr
4905.5-144.5 (-2.86%)
4886.50
5066
1,90,351Cr
1143-48 (-4.03%)
1130.50
1187
1,14,833Cr
1394.7-28.8 (-2.02%)
1389.40
1426.10
1,14,163Cr
1868.5-70 (-3.61%)
1811.70
1949
1,00,660Cr
2132-39.5 (-1.82%)
2132
2192
98,431Cr
2368.8-14.1 (-0.59%)
2341.20
2419.20
98,305Cr
1155-23 (-1.95%)
1154.40
1179.90
96,906Cr
1637.3-8 (-0.49%)
1626.60
1717
95,300Cr
1575.7+43.5 (2.84%)
1504.10
1596.60
17,715Cr

Onesource Specialty Pharma Ltd Annual Results Key Takeaways

Operating profit (before other income, interest and exceptional items) was ₹127.15Cr; with other income of ₹3.8Cr, profit before interest and tax came to ₹51.1Cr. Interest expense was ₹30.81Cr; PBT before exceptional items stood at ₹20.29Cr. Cost mix (full year): raw materials ₹436.75Cr; employee cost ₹242.25Cr; depreciation ₹71.75Cr; other expenses ₹325.68Cr. Basis: consolidated annual results.

Onesource Specialty Pharma Ltd Quaterly Results Key Takeaways

Onesource Specialty Pharma Ltd reported ₹449.02Cr total income from operations in Jun 2026, softer than ₹428.22Cr in Mar 2026 but higher than ₹327.27Cr in Jun 2025. Operating profit (before other income, interest and exceptional items) was ₹127.15Cr; with other income of ₹3.8Cr, profit before interest and tax came to ₹51.1Cr. Interest expense was ₹30.81Cr, taking profit before tax to ₹20.29Cr. After tax of ₹-₹4.7Cr, profit after tax stood at ₹25Cr (vs ₹4.6Cr in Mar 2026 and ₹-₹18.6Lakh in Jun 2025).